Get the Stockscreener App
308.44
5.12%
15.03
After Hours:
308.44
Madrigal Pharmaceuticals Inc stock is traded at $308.44, with a volume of 688.42K.
It is up +5.12% in the last 24 hours and down -2.73% over the past month.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
See More
Previous Close:
$293.41
Open:
$294
24h Volume:
688.42K
Relative Volume:
1.65
Market Cap:
$6.73B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-16.03
EPS:
-19.24
Net Cash Flow:
$-438.32M
1W Performance:
+1.29%
1M Performance:
-2.73%
6M Performance:
+15.18%
1Y Performance:
+39.54%
1-Day Range:
$293.00
$312.52
1-Week Range:
$289.80
$315.09
52-Week Range:
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
308.44 | 6.73B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Geode Capital Management LLC Boosts Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
9,031 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Acquired by Wellington Management Group LLP - MarketBeat
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Profit Outlook - Yahoo Finance
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Barclays PLC - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra launch key to stock's future - Investing.com
Y Intercept Hong Kong Ltd Takes Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
How To Trade (MDGL) - Stock Traders Daily
State Street Corp Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Brokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) PT at $347.33 - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4.74 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's potential drives stock outlook - Investing.com India
Madrigal Pharmaceuticals' SWOT analysis: rezdiffra's potential drives stock outlook By Investing.com - Investing.com Australia
XTX Topco Ltd Invests $1.04 Million in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
BNP Paribas Financial Markets Has $2.07 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Position Lessened by The Manufacturers Life Insurance Company - MarketBeat
Madrigal Pharmaceuticals (LTS:0JXI) 9-Day RSI : 50.46 (As of Dec. 05, 2024) - GuruFocus.com
Madrigal Pharmaceuticals director Fred Craves sells shares worth $1.14 million - Investing.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is RTW Investments LP's Largest Position - MarketBeat
How to Take Advantage of moves in (MDGL) - Stock Traders Daily
Cinctive Capital Management LP Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Breakeven? - Simply Wall St
Charles Schwab Investment Management Inc. Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Fmr LLC Sells 5,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL
Martingale Asset Management L P Takes Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals (FRA:YDO1) 9-Day RSI : 56.49 (As of Dec. 01, 2024) - GuruFocus.com
Madrigal Pharmaceuticals (FRA:YDO1) Total Assets : €967.01 Mil (As of Sep. 2024) - GuruFocus.com
Erste Asset Management GmbH Makes New $49.75 Million Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Braidwell LP Takes $39.01 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
MDGL (Madrigal Pharmaceuticals) EBITDA : $-502.65 Mil (TTM As of Sep. 2024) - GuruFocus.com
Vestal Point Capital LP Buys New Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
1,852 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Blueshift Asset Management LLC - MarketBeat
MDGL (Madrigal Pharmaceuticals) Shares Outstanding (EOP) : 21.81 Mil (As of Sep. 2024) - GuruFocus.com
Advantage Alpha Capital Partners LP Makes New $349,000 Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Intech Investment Management LLC Takes $1.28 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals (LTS:0JXI) Total Stockholders Equi - GuruFocus.com
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move - MSN
Eagle Asset Management Inc. Makes New Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
MDGL (Madrigal Pharmaceuticals) Total Inventories : $8.72 Mil (As of Sep. 2024) - GuruFocus.com
When (MDGL) Moves Investors should Listen - Stock Traders Daily
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra - MSN
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Madrigal Pharmaceuticals Engages with Investors at Key Conferences - MSN
Connor Clark & Lunn Investment Management Ltd. Decreases Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal shares hold as Cowen maintains price target on new data - Investing.com Canada
Madrigal Pharmaceuticals (FRA:YDO1) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra (MDGL:NASDAQ) - Seeking Alpha
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):